$398 Million is the total value of DAFNA Capital Management LLC's 87 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 56.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FATE | Buy | FATE THERAPEUTICS INC | $21,775,000 | +6.7% | 372,160 | +8.1% | 5.48% | +1.1% |
| ACET | Buy | ADICET BIO INC | $12,823,000 | +334.7% | 733,172 | +94.8% | 3.22% | +311.7% |
| MRUS | Buy | MERUS N V | $7,190,000 | +147.7% | 226,089 | +71.3% | 1.81% | +134.8% |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $6,491,000 | +320.9% | 296,535 | +267.4% | 1.63% | +299.0% |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $6,042,000 | +215.7% | 1,787,569 | +241.0% | 1.52% | +199.0% |
| CSII | Buy | CARDIOVASCULAR SYS INC | $5,390,000 | -15.3% | 286,988 | +48.1% | 1.36% | -19.7% |
| RVMD | Buy | REVOLUTION MEDICINES INC | $5,342,000 | -7.4% | 212,231 | +1.2% | 1.34% | -12.3% |
| MEIP | Buy | MEI PHARMA INC | $4,712,000 | +166.4% | 1,764,846 | +175.3% | 1.18% | +152.7% |
| ISEE | Buy | IVERIC BIO INC | $4,614,000 | +31.3% | 275,976 | +27.6% | 1.16% | +24.5% |
| NTUS | Buy | NATUS MED INC | $4,524,000 | +88.6% | 190,635 | +99.3% | 1.14% | +78.9% |
| New | PARDES BIOSCIENCES INC | $3,822,000 | – | 233,500 | +100.0% | 0.96% | – | |
| ALEC | Buy | ALECTOR INC | $3,206,000 | +30.8% | 155,247 | +44.5% | 0.81% | +24.0% |
| AXGN | New | AXOGEN INC | $3,112,000 | – | 332,103 | +100.0% | 0.78% | – |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $2,522,000 | -23.6% | 190,663 | +0.8% | 0.63% | -27.6% |
| BMEA | New | BIOMEA FUSION INC | $2,339,000 | – | 313,923 | +100.0% | 0.59% | – |
| RIGL | Buy | RIGEL PHARMACEUTICALS INC | $2,329,000 | -20.7% | 879,000 | +8.7% | 0.59% | -24.8% |
| TPTX | Buy | TURNING POINT THERAPEUTICS I | $2,216,000 | -20.5% | 46,452 | +10.7% | 0.56% | -24.6% |
| ETNB | Buy | 89BIO INC | $1,891,000 | -23.8% | 144,653 | +14.2% | 0.48% | -27.7% |
| RGLS | New | REGULUS THERAPEUTICS INC | $1,750,000 | – | 5,555,555 | +100.0% | 0.44% | – |
| IPSC | Buy | CENTURY THERAPEUTICS INC | $1,588,000 | -21.1% | 100,135 | +25.2% | 0.40% | -25.3% |
| KURA | Buy | KURA ONCOLOGY INC | $1,552,000 | -17.8% | 110,829 | +9.9% | 0.39% | -22.2% |
| SURF | New | SURFACE ONCOLOGY INC | $1,506,000 | – | 315,000 | +100.0% | 0.38% | – |
| ASND | New | ASCENDIS PHARMA A/Ssponsored adr | $1,480,000 | – | 11,000 | +100.0% | 0.37% | – |
| NGM | Buy | NGM BIOPHARMACEUTICALS INC | $1,425,000 | +3.6% | 80,485 | +22.9% | 0.36% | -1.9% |
| RDUS | Buy | RADIUS HEALTH INC | $1,328,000 | +637.8% | 191,978 | +1224.0% | 0.33% | +595.8% |
| New | THESEUS PHARMACEUTICALS INC | $1,236,000 | – | 97,500 | +100.0% | 0.31% | – | |
| WVE | New | WAVE LIFE SCIENCES LTD | $1,225,000 | – | 390,161 | +100.0% | 0.31% | – |
| NXTC | Buy | NEXTCURE INC | $1,126,000 | -9.0% | 187,696 | +2.3% | 0.28% | -13.7% |
| BDTX | New | BLACK DIAMOND THERAPEUTICS I | $1,099,000 | – | 206,100 | +100.0% | 0.28% | – |
| LRMR | Buy | LARIMAR THERAPEUTICS INC | $757,000 | +1.7% | 70,177 | +8.8% | 0.19% | -3.6% |
| SCYX | New | SCYNEXIS INC | $740,000 | – | 121,242 | +100.0% | 0.19% | – |
| CMPX | New | COMPASS THERAPEUTICS INC | $622,000 | – | 196,091 | +100.0% | 0.16% | – |
| PHVS | Buy | PHARVARIS N V | $528,000 | -15.1% | 36,720 | +4.7% | 0.13% | -19.4% |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $511,000 | – | 136,266 | +100.0% | 0.13% | – |
| ANNX | Buy | ANNEXON INC | $354,000 | -18.4% | 30,796 | +32.2% | 0.09% | -22.6% |
| LCTX | New | LINEAGE CELL THERAPEUTICS IN | $196,000 | – | 80,000 | +100.0% | 0.05% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.